MX2015013387A - Celulas madre mesenquimales primarias inmunoprotectoras y metodos. - Google Patents
Celulas madre mesenquimales primarias inmunoprotectoras y metodos.Info
- Publication number
- MX2015013387A MX2015013387A MX2015013387A MX2015013387A MX2015013387A MX 2015013387 A MX2015013387 A MX 2015013387A MX 2015013387 A MX2015013387 A MX 2015013387A MX 2015013387 A MX2015013387 A MX 2015013387A MX 2015013387 A MX2015013387 A MX 2015013387A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- stem cells
- mesenchymal stem
- primary mesenchymal
- polypeptides
- Prior art date
Links
- 230000002480 immunoprotective effect Effects 0.000 title abstract 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 108010002335 Interleukin-9 Proteins 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
Abstract
Se describen en la presente células madre mesenquimales primarias inmunoprotectoras (IP-MSC) que expresan episomalmente polipéptidos inmunoreactivos múltiples que dirigen específicamente un patógeno (por ejemplo, un especie infecciosa de virus, bacteria, o parásito) o toxina. La IPMSC expresa dos o más (por ejemplo, 2 hasta alrededor de 100) polipéptidos inmunoreactivos (por ejemplo, anticuerpos completos, anticuerpos de cadena sencilla (ScFV), fragmentos de anticuerpo Fab o F(ab)2, diacuerpos, tricuerpos, y similares), y opcionalmente uno o más de otros polipéptidos inmunomoduladores, por ejemplo, una citoquina tal como una interleucina (por ejemplo, IL-2, IL-4, IL-6, IL-7, IL-9, e IL-12), un interferón (por ejemplo, IFNa, IFNß, o IFN?), y similares, que pueden aumentar la efectividad de los polipéptidos inmunoreactivos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/826,285 US9101597B2 (en) | 2013-03-14 | 2013-03-14 | Immunoprotective primary mesenchymal stem cells and methods |
PCT/US2014/025941 WO2014160157A1 (en) | 2013-03-14 | 2014-03-13 | Immunoprotective primary mesenchymal stem cells and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015013387A true MX2015013387A (es) | 2016-08-11 |
MX366419B MX366419B (es) | 2019-07-08 |
Family
ID=51527936
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000704A MX2019000704A (es) | 2013-03-14 | 2014-03-13 | Celulas madre mesenquimales primarias inmunoprotectoras y metodos. |
MX2015013387A MX366419B (es) | 2013-03-14 | 2014-03-13 | Celulas madre mesenquimales primarias inmunoprotectoras y metodos. |
MX2019008195A MX2019008195A (es) | 2013-03-14 | 2015-09-14 | Celulas madre mesenquimales primarias inmunoprotectoras y metodos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000704A MX2019000704A (es) | 2013-03-14 | 2014-03-13 | Celulas madre mesenquimales primarias inmunoprotectoras y metodos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008195A MX2019008195A (es) | 2013-03-14 | 2015-09-14 | Celulas madre mesenquimales primarias inmunoprotectoras y metodos. |
Country Status (13)
Country | Link |
---|---|
US (4) | US9101597B2 (es) |
EP (1) | EP2968611B1 (es) |
JP (1) | JP6566932B2 (es) |
CN (1) | CN105188768B (es) |
AR (1) | AR095368A1 (es) |
AU (1) | AU2014244057B2 (es) |
CA (1) | CA2906592C (es) |
EA (1) | EA201591673A1 (es) |
ES (1) | ES2881383T3 (es) |
HK (1) | HK1219050A1 (es) |
MX (3) | MX2019000704A (es) |
TW (2) | TWI650420B (es) |
WO (1) | WO2014160157A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101597B2 (en) * | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
US11357866B2 (en) * | 2013-04-03 | 2022-06-14 | The Administrators Of The Tulane Educational Fund | Expression of HIV inhibitors by mesenchymal stem cells |
EP3656387A3 (en) | 2014-08-18 | 2020-07-01 | Apceth GmbH & Co. KG | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
WO2016196740A1 (en) * | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
WO2017136539A1 (en) | 2016-02-04 | 2017-08-10 | Hare Joshua M | Mesenchymal stem cells as vaccine adjuvants and methods for using the same |
EP3462883B1 (en) * | 2016-06-07 | 2023-08-16 | The Pacific Heart, Lung,&Blood Institute | Compositions and their use in treating cancer |
EP3548075A4 (en) * | 2016-12-05 | 2020-11-25 | The Administrators of The Tulane Educational Fund | MONOCLONAL ARENAVIRUS ANTIBODIES AND USES |
US11104918B2 (en) * | 2019-09-05 | 2021-08-31 | Crispr Therapeutics Ag | Universal donor cells |
CN111363045B (zh) * | 2020-02-18 | 2021-12-17 | 厦门大学 | 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法 |
WO2021181399A1 (en) * | 2020-03-12 | 2021-09-16 | Exostem Biotec Ltd. | Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis |
EP3881853A1 (en) * | 2020-03-20 | 2021-09-22 | Promethera Therapeutics Sa | Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation |
US20210299246A1 (en) * | 2020-03-27 | 2021-09-30 | R. Brannon Claytor | Methods and compositions for therapeutic treatment of viral or virally-induced infections and conditions, and anti-viral compositions and their production |
AU2021414617A1 (en) | 2020-12-31 | 2023-08-10 | Crispr Therapeutics Ag | Universal donor cells |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040039186A1 (en) * | 1997-02-28 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Self-regulated apoptosis of inflammatory cells by gene therapy |
WO1999015199A1 (en) | 1997-09-20 | 1999-04-01 | Osiris Therapeutics, Inc. | Antigen presenting mesenchymal stem cells |
CA2436091A1 (en) | 2001-01-26 | 2002-08-01 | Abgenix, Inc. | Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
US20070196365A1 (en) * | 2001-02-20 | 2007-08-23 | Dov Zipori | Immunoglobulin heavy chain variants expressed in mesenchymal cells and therapeutic uses thereof |
AU2002325758A1 (en) * | 2001-09-20 | 2003-04-01 | Centre For Translational Research In Cancer | Cultured stromal cells and uses thereof |
JPWO2005094846A1 (ja) * | 2004-03-30 | 2008-02-14 | 株式会社レノメディクス研究所 | プリオン病治療剤およびその製造方法 |
CN101166546A (zh) * | 2005-01-21 | 2008-04-23 | 因特罗根治疗公司 | 允许靶细胞长期暴露于治疗性和预防性核酸的局部施用 |
SG195394A1 (en) | 2005-05-18 | 2013-12-30 | Biofactura Inc | Compositions and methods for metabolic selection of transfected cells |
CN1872344A (zh) * | 2005-06-01 | 2006-12-06 | 上海二医新生基因科技有限公司 | 人异体间质干细胞(携带治疗基因)的基因治疗方法 |
EP2024393A2 (en) | 2006-05-15 | 2009-02-18 | Sea Lane Biotechnologies,llc. | Neutralizing antibodies to influenza viruses |
EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
JP5773366B2 (ja) * | 2008-04-21 | 2015-09-02 | ティシュー リジェネレイション セラピューティックス、インコーポレイテッド | 生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞 |
US9707322B2 (en) * | 2012-12-21 | 2017-07-18 | University Of Connecticut | Gradient porous scaffolds |
US10472647B2 (en) * | 2012-12-21 | 2019-11-12 | The Administrators Of The Tulane Educational Fund | Primary mesenchymal stem cells as a vaccine platform |
US9101597B2 (en) * | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
-
2013
- 2013-03-14 US US13/826,285 patent/US9101597B2/en active Active
-
2014
- 2014-03-12 AR ARP140100907A patent/AR095368A1/es unknown
- 2014-03-13 JP JP2016502003A patent/JP6566932B2/ja active Active
- 2014-03-13 CN CN201480026798.5A patent/CN105188768B/zh active Active
- 2014-03-13 WO PCT/US2014/025941 patent/WO2014160157A1/en active Application Filing
- 2014-03-13 MX MX2019000704A patent/MX2019000704A/es unknown
- 2014-03-13 AU AU2014244057A patent/AU2014244057B2/en active Active
- 2014-03-13 EA EA201591673A patent/EA201591673A1/ru unknown
- 2014-03-13 TW TW103109173A patent/TWI650420B/zh active
- 2014-03-13 EP EP14774631.7A patent/EP2968611B1/en active Active
- 2014-03-13 TW TW107138753A patent/TWI689590B/zh active
- 2014-03-13 ES ES14774631T patent/ES2881383T3/es active Active
- 2014-03-13 MX MX2015013387A patent/MX366419B/es active IP Right Grant
- 2014-03-13 CA CA2906592A patent/CA2906592C/en active Active
-
2015
- 2015-07-17 US US14/802,247 patent/US10357562B2/en active Active
- 2015-09-14 MX MX2019008195A patent/MX2019008195A/es unknown
-
2016
- 2016-06-21 HK HK16107097.9A patent/HK1219050A1/zh unknown
-
2019
- 2019-05-30 US US16/426,911 patent/US11123427B2/en active Active
-
2021
- 2021-09-17 US US17/477,725 patent/US20210401984A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201907005A (zh) | 2019-02-16 |
CN105188768B (zh) | 2019-06-28 |
JP6566932B2 (ja) | 2019-08-28 |
US20210401984A1 (en) | 2021-12-30 |
WO2014160157A1 (en) | 2014-10-02 |
MX366419B (es) | 2019-07-08 |
EP2968611A4 (en) | 2016-08-17 |
TWI689590B (zh) | 2020-04-01 |
US20160129110A1 (en) | 2016-05-12 |
EP2968611B1 (en) | 2021-05-05 |
ES2881383T3 (es) | 2021-11-29 |
CA2906592C (en) | 2022-01-18 |
US20190282694A1 (en) | 2019-09-19 |
CA2906592A1 (en) | 2014-10-02 |
US11123427B2 (en) | 2021-09-21 |
AR095368A1 (es) | 2015-10-14 |
MX2019008195A (es) | 2019-09-11 |
US9101597B2 (en) | 2015-08-11 |
AU2014244057A1 (en) | 2015-10-29 |
US20140271580A1 (en) | 2014-09-18 |
US10357562B2 (en) | 2019-07-23 |
TW201514301A (zh) | 2015-04-16 |
EA201591673A1 (ru) | 2016-01-29 |
JP2016518819A (ja) | 2016-06-30 |
EP2968611A1 (en) | 2016-01-20 |
TWI650420B (zh) | 2019-02-11 |
CN105188768A (zh) | 2015-12-23 |
AU2014244057B2 (en) | 2018-12-06 |
HK1219050A1 (zh) | 2017-03-24 |
MX2019000704A (es) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008195A (es) | Celulas madre mesenquimales primarias inmunoprotectoras y metodos. | |
NZ736026A (en) | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
PH12017502019A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
JO3772B1 (ar) | صيغة جسم مضاد لـ cgrp | |
MX2022012749A (es) | Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas. | |
MX2018016364A (es) | Anticuerpos anti-pd-l1. | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
MX2019007020A (es) | Anticuerpos il-11. | |
MY186352A (en) | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies | |
MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
WO2018119425A3 (en) | Anti-lilrb3 antibodies and methods of use thereof | |
MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
WO2016173605A8 (en) | Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof | |
PH12020550025A1 (en) | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof | |
MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
EP3098316A4 (en) | Human-derived insect-resistant gene and anti-cry1b toxin idiotype single-chain antibody encoded thereby and application thereof | |
MX2018006410A (es) | Proteinas de union a cd131 y usos de las mismas. | |
PH12016502535A1 (en) | Interferon alpha and omega antibody antagonists | |
DK3455261T3 (da) | Anti-ror2-antistoffer, antistoffragmenter, immunkonjugater deraf og anvendelser deraf | |
MX2019013370A (es) | Constructos de anticuerpos de ácidos nucleicos optimizados. | |
EP3048171A4 (en) | Anthropogenic insect-resistant gene and cry1c toxin idiotype single-chain antibody encoded thereby and application thereof | |
WO2018138681A9 (en) | Hemagglutinin-specific antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |